基于非红系细胞计数骨髓原始细胞可改善骨髓增生异常综合征的预后预测,并优化修订版国际预后评分系统(IPSS-R)中危组的定义
该研究在3924例骨髓增生异常综合征(MDS)患者(含498例红系优势型MDS)中,评估按非红系细胞(NEC)计数原始细胞计算IPSS-R是否改善预后分层。结果显示,原中危组中24%被重分类至高危组,其总生存期(OS)及进展至急性髓系白血病(AML)时间均缩短;红系优势型MDS中该比例为51%。作者结论认为此简便方法可改善MDS患者的预后评估。
要点
- 按非红系细胞计数原始细胞计算IPSS-R,可使原中危组中24%患者重分类至高危组,其OS及进展至AML时间缩短。
- 红系优势型MDS中,原中危组51%患者被重分类至高危组,OS及进展至AML时间缩短。
- 仅在按非红系细胞计数时,IPSS-R才能将红系优势型MDS系列分为OS差异显著的五组。
核心结论
- 按非红系细胞计数原始细胞计算IPSS-R可改善MDS患者的预后评估,并优化中危组的定义。
- 作者结论认为这种简便易行的方法改善了MDS患者的预后评估。
研究设计与样本
- 研究纳入来自GESMD的3924例MDS患者,其中498例为红系优势型MDS(MDS-E)。
- 研究评估了总 nucleated cells(TNCs)与NECs来源的原始细胞百分比,并比较按NECs计数原始细胞计算IPSS-R对预后的影响。
主要发现
- 原中危组中24%患者被重分类至高危组,其OS及进展至AML时间较仍留在中危组者缩短。
- 重分类后低危组患者生存期较前延长,而高危组患者维持该不良预后组预期的结局(中位OS < 20个月)。
- 该方法尤其有助于识别有死于AML风险的患者。
- 红系优势型MDS中,原中危组51%患者被重分类至高危组,其OS及进展至AML时间缩短。
- 红系优势型MDS中,仅当按NECs评估原始细胞时,IPSS-R才能将该系列分为OS差异显著的五组。
关键数值与推荐
- 原中危组中24%患者被重分类至高危组,其OS及进展至AML时间较仍留在中危组者缩短。
- 红系优势型MDS原中危组中51%患者被重分类至高危组,其OS及进展至AML时间缩短。
- 重分类后高危组患者中位OS < 20个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Revised International Prognostic Scoring System (IPSS-R) has been recognized as the score with the best outcome prediction capability in MDS, but this brought new concerns about the accurate prognostication of patients classified into the intermediate risk category. The correct enumeration of blasts is essential in prognostication of MDS. Recent data evidenced that considering blasts from nonerythroid cellularity (NECs) improves outcome prediction in the context of IPSS and WHO classification. We assessed the percentage of blasts from total nucleated cells (TNCs) and NECs in 3924 MDS patients from the GESMD, 498 of whom were MDS with erythroid predominance (MDS-E). We assessed if calculating IPSS-R by enumerating blasts from NECs improves prognostication of MDS. Twenty-four percent of patients classified into the intermediate category were reclassified into higher-risk categories and showed shorter overall survival (OS) and time to AML evolution than those who remained into the intermediate one. Likewise, a better distribution of patients was observed, since lower-risk patients showed longer survivals than previously whereas higher-risk ones maintained the outcome expected in this poor prognostic group (median OS < 20 months). Furthermore, our approach was particularly useful for detecting patients at risk of dying with AML. Regarding MDS-E, 51% patients classified into the intermediate category were reclassified into higher-risk ones and showed shorter OS and time to AML. In this subgroup of MDS, IPSS-R was capable of splitting our series in five groups with significant differences in OS only when blasts were assessed from NECs. In conclusion, our easy-applicable approach improves prognostic assessment of MDS patients.
引用
- Calvo X, Arenillas L, Luño E, et al. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Am J Hematol. 2017. PMID: 28370234. doi:10.1002/ajh.24732
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。